SCHEMBL23926136

SCHEMBL23926136

Oc1cccc(-c2ccnc(Cl)n2)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.50
HSD17B14 Q9BPX1 15/20 0.47
KDM1A O60341 1/20 0.42
PDPK1 O15530 1/20 0.37
CCNT1 O60563 1/20 0.37
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
HTR1A P08908 1/20 0.37
CCNB1 P14635 1/20 0.37
PRKACA P17612 1/20 0.37
CCNA2 P20248 1/20 0.37
PRKACG P22612 1/20 0.37
PRKACB P22694 1/20 0.37
CDK2 P24941 1/20 0.37
HTR2B P41595 1/20 0.37
GSK3B P49841 1/20 0.37
CDK9 P50750 1/20 0.37
CCNA1 P78396 1/20 0.37
CDK5 Q00535 1/20 0.37
SLC6A3 Q01959 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31011602 0.83 CYP19A1 (0.45) KMOKDM1APDPK1CCNT1CCNB2
SCHEMBL3626006 0.83 CYP19A1 (0.45) KMOKDM1APDPK1CCNT1CCNB2
SCHEMBL22090261 0.79 KMO (0.59) KMOHSD17B14
SCHEMBL23943387 0.78 KDM1A (0.46) KMOKDM1AHTR1AHTR2BGSK3B
SCHEMBL2350242 0.76 NPC1 (0.47) KMO
SCHEMBL15228870 0.76 AAK1 (0.42) KMO
SCHEMBL3627132 0.75 KDM1A (0.48) KMOKDM1ACDK1CDK2
SCHEMBL30956563 0.75 KMO (0.48) KMOHSD17B14CCNT1CDK9SLC6A3
SCHEMBL21811385 0.75 MAPT (0.46) KMOCDK2CDK5CDK5R1
SCHEMBL17453624 0.74 ALDH1A1 (0.41) KMOPDPK1CDK1PRKACACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 KMO 1170/4885HSD17B14 7/4885KDM1A 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.